Portnoy Jay M, Dinakar Chitra
Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA.
Expert Opin Pharmacother. 2004 Jan;5(1):125-35. doi: 10.1517/14656566.5.1.125.
Cetirizine hydrochloride is an orally-active and selective histamine (H(1))-receptor antagonist. It is a second-generation antihistamine and a human metabolite of hydroxyzine. Therefore, its principal effects are mediated via selective inhibition of peripheral H(1) receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth has been seen more commonly with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for receptors other than H(1) receptors. Auto-radiographical studies with radiolabelled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H(1) receptors. Impairment of CNS function is comparable to other low-sedating antihistamines at the recommended dose of 10 mg/day for adults. It has anti-inflammatory properties that may play a role in asthma management. It does not interact with concomitantly administered medications, it has no cardiac adverse effects, and it does not appear to be associated with teratogenicity. Cetirizine is predominantly eliminated by the kidneys with a mean elimination half-life is 8.3 h. It is rapidly absorbed, and significant clinical inhibition of a wheal and flare response occurs in infants, children and adults within 20 min of a single oral dose and persists for 24 h. No tolerance to the wheal and flare response occurs even after 1 month of daily treatment. The clinical efficacy of cetirizine for allergic respiratory diseases has been established in numerous trials. There is evidence that cetirizine improves symptoms of urticaria. Concomitant use of cetirizine also decreases the duration and amount of topical anti-inflammatory preparations needed for the treatment of atopic dermatitis. Interestingly, several clinical studies suggest that cetirizine may be useful in the treatment and prevention of mild asthma.
盐酸西替利嗪是一种口服活性的选择性组胺(H(1))受体拮抗剂。它是第二代抗组胺药,也是羟嗪的人体代谢产物。因此,其主要作用是通过选择性抑制外周H(1)受体介导的。西替利嗪的抗组胺活性已在多种动物和人体模型中得到证实。体内和体外动物模型显示其抗胆碱能和抗5-羟色胺能活性可忽略不计。然而,在临床研究中,与安慰剂相比,服用西替利嗪时口干更为常见。体外受体结合研究表明,除H(1)受体外,对其他受体无明显亲和力。用放射性标记的西替利嗪在大鼠体内进行的放射自显影研究表明,其进入脑内的量可忽略不计。在小鼠体内进行的体外实验表明,全身给药的西替利嗪不会显著占据脑内H(1)受体。在成人推荐剂量为每日10 mg时,其对中枢神经系统功能的损害与其他低镇静作用的抗组胺药相当。它具有抗炎特性,可能在哮喘治疗中发挥作用。它不与同时服用的药物相互作用,无心脏不良反应,且似乎与致畸性无关。西替利嗪主要通过肾脏消除,平均消除半衰期为8.3小时。它吸收迅速,单次口服给药后20分钟内,婴儿、儿童和成人的风团和潮红反应即受到显著临床抑制,并持续24小时。即使每日治疗1个月后,对风团和潮红反应也不会产生耐受性。西替利嗪对过敏性呼吸道疾病的临床疗效已在众多试验中得到证实。有证据表明西替利嗪可改善荨麻疹症状。同时使用西替利嗪还可减少治疗特应性皮炎所需局部抗炎制剂的使用时间和用量。有趣的是,多项临床研究表明,西替利嗪可能对轻度哮喘的治疗和预防有用。